<DOC>
	<DOCNO>NCT01235442</DOCNO>
	<brief_summary>The primary hypothesis trial addition short course clobetasol propionate foam etanercept monotherapy subject moderate severe plaque psoriasis yield great efficacy compare etanercept monotherapy , measure PASI 75 Week 12 .</brief_summary>
	<brief_title>Evaluate Efficacy , Safety Topical Therapy Etanercept Subjects With Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Subject stable moderate severe plaque psoriasis least 6 month Subject involve BSA ≥ 10 % PASI ≥ 10 screen baseline . Subject candidate systemic therapy phototherapy opinion investigator Subject active guttate , erythrodermic , pustular psoriasis time screen visit . Subject evidence skin condition time screen visit ( eg , eczema ) would interfere evaluation effect etanercept and/orclobetasol propionate foam psoriasis . Subject diagnose medicationinduced medication exacerbate psoriasis Subject active Common Toxicity Criteria ( CTC ) grade 2 high infection Subject significant concurrent medical condition laboratory abnormality define study protocol . Subject use follow therapy within 14 day first dose : UVB therapy topical psoriasis therapy Class I II topical steroid . Subject use follow therapy within 28 day first dose : Class I II topical steriods , UVA therapy ( without psoralen ) , systemic psoriasis therapy Subject use one biologic therapy ( interleukin ( IL ) 12/IL23 inhibitor ) within 3 month first dose Subject use IL12/IL23 inhibitor within 6 month first dose etanercept Subject ever use efalizumab ( Raptiva® ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Topical</keyword>
	<keyword>etanercept</keyword>
	<keyword>clobetasol propionate</keyword>
</DOC>